Adc Therapeutics is a biotechnology company focused on the development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancers
The company leverages its proprietary technology platform to create innovative therapies that specifically target and kill cancer cells while sparing healthy tissue, thereby enhancing treatment efficacy and reducing side effects. Adc Therapeutics aims to address unmet medical needs in oncology by advancing its pipeline of drug candidates through clinical trials, and its research efforts are guided by a commitment to improve patient outcomes in various types of malignancies.
LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 113,700 of the Company’s common shares to six new employees on October 1, 2024 (each, a “Grant”).
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,900 of the Company’s common shares to four new employees on September 3, 2024 (each, a “Grant”).
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in September:
LAUSANNE, Switzerland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 38,600 of the Company’s common shares to three new employees on August 1, 2024 (each, a “Grant”).
LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 6, 2024, at 8:30 a.m. EDT to report financial results for the second quarter 2024 and provide operational updates.
LAUSANNE, Switzerland, July 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that the Company has made grants of options to purchase an aggregate of 172,400 of the Company’s common shares to six new employees on July 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024.
LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company’s common shares to three new employees on June 3, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.
LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET.
LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 2:00 p.m. ET.
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET.
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price). The gross proceeds from the offering, before deducting the underwriting discount and offering expenses payable by the Company and assuming no exercise of the pre-funded warrants, are expected to be approximately $105.0 million. The offering is expected to close on May 8, 2024, subject to customary closing conditions.
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA®
LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that the Company has made grants of options to purchase an aggregate of 147,600 of the Company’s common shares to four new employees on May 1, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.
LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSEADCT) today announced that it will host a conference call and live webcast on Monday, May 6, 2024 at 8:30 a.m. EDT to report financial results for the first quarter 2024 and provide updates on recent progress against key catalysts from the pipeline.
